Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03694431 · ClinicalTrials.gov registry record · NA
Comparative Trial of Home-Based Palliative Care
A NA study, sponsored by Kaiser Permanente.
- Terminated
- Registry status
- NA
- Development phase
- 3,999
- Enrollment target
NCT03694431: Clinical Trial NA study, sponsored by Kaiser Permanente.
NCT03694431 is a NA study that was terminated before completion, run by Kaiser Permanente. The registered enrollment target is 3,999 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (185% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03694431, a NA study, was terminated before completion, sponsored by Kaiser Permanente.
- TERMINATED
- Registry status
- NA
- Development phase
- 3,999 participants
- Enrollment target
Study Summary
Background: To effectively alleviate suffering and improve quality of life for patients with serious illness and their caregivers, palliative care (PC) services must be offered across multiple settings. Research is needed to determine how best to optimize home-based palliative care (HBPC) services to meet the needs of individuals with high symptom burden and functional limitations. Aim: The investigators will compare a standard HBPC model that includes routine home visits by a nurse and provider with a more efficient tech-supported HBPC model that promotes timely inter-professional team coordination via synchronous video consultation with the provider while the nurse is in the patient's home. The investigators hypothesize that tech-supported HBPC will be as effective as standard HBPC. Design: Cluster randomized trial. Registered nurses (n\~130) will be randomly assigned to the tech-supported or standard HBPC model so that half of the patient-caregiver dyads will receive one of the two models. Setting/Participants: Kaiser Permanente (15 Southern California and Oregon sites). Patients (n=10,000) with any serious illness and a prognosis of 1-2 years and their caregivers (n=4,800) Methods: Patients and caregivers will receive standard PC services: comprehensive needs assessment and care planning, pain and symptom management, education/skills training, medication management, emotional/spiritual support; care coordination, referral to other services, and 24/7 phone assistance. Results: Primary patient outcomes: symptom improvement at 1 month and days spent at home in the last six months of life; caregiver outcome: perception of preparedness for caregiving. Conclusion: Should the more efficient tech-supported HBPC model achieves comparable improvements in outcomes that matter most to patients and caregivers, this would have a lasting impact on PC practice and policy.
Primary Outcome
The ESAS is a 10-item survey measuring symptom severity. Scores range from 0-100 with higher scores indicating worse symptoms.
Interventions
- OTHER Tech-supported HBPC
- OTHER Standard HBPC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,999 participants |
| Start Date | 2019-01-07 |
| Est. Completion | 2020-01-24 |
| Phase | NA |
Why NCT03694431 stopped before completion
NCT03694431 is an interventional study that assigns participants to a tested intervention. Its 3,999 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (185% higher).
The record links to 0 conditions, and to 2 interventions - of which Tech-supported HBPC is the first listed.
NCT03694431 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03694431 about?
NCT03694431 is a clinical study titled "Comparative Trial of Home-Based Palliative Care". Background: To effectively alleviate suffering and improve quality of life for patients with serious illness and their caregivers, palliative care (PC) services must be offered across multiple settings. Research is needed to determine how best to optimize home-based palliative care (HBPC) services t...
What is the current status of trial NCT03694431?
This trial is currently terminated. It is a NA study. The enrollment target is 3,999 participants. The study started on 2019-01-07. Estimated completion is 2020-01-24.
What interventions are being tested in trial NCT03694431?
The interventions under investigation include: Tech-supported HBPC (OTHER), Standard HBPC (OTHER).
Who is sponsoring clinical trial NCT03694431?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03694431's enrollment target sits among peer trials
3,999 36th of 2000 higher than 1,965 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00227253 · 4,000 participants
Chromosome 18 Clinical Research Center
- NCT00811148 · 4,000 participants
Florida Center for Brain Tumor Research
- NCT00897117 · 4,000 participants
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
- NCT00899301 · 4,000 participants
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI